Proteomics Laboratory for Clinical and Translational Research, Carolinas HealthCare System, Charlotte, NC 28203, United States.
Omics Core Laboratory, Research Institute, National Cancer Center, Goyang 10408, Korea.
Mol Cells. 2018 Mar 31;41(3):179-187. doi: 10.14348/molcells.2018.2110. Epub 2018 Mar 9.
Proteomic analysis of extracellular vesicles (EVs) from biological fluid is a powerful approach to discover potential biomarkers for human diseases including cancers, as EV secreted to biological fluids are originated from the affected tissue. In order to investigate significant molecules related to the pathogenesis of bladder cancer, EVs were isolated from patient urine which was analyzed by mass spectrometry based proteomics. Comparison of the EV proteome to the whole urine proteome demonstrated an increased number of protein identification in EV. Comparative MS analyses of urinary EV from control subjects and bladder cancer patients identified a total of 1,222 proteins. Statistical analyses provided 56 proteins significantly increased in bladder cancer urine, including proteins for which expression levels varied by cancer stage (P-value < 0.05). While urine represents a valuable, noninvasive specimen for biomarker discovery in urologic cancers, there is a high degree of intra- and inter-individual variability in urine samples. The enrichment of urinary EV demonstrated its capability and applicability of providing a focused identification of biologically relevant proteins in urological diseases.
从生物体液中分离细胞外囊泡 (EV) 的蛋白质组学分析是发现包括癌症在内的人类疾病潜在生物标志物的有力方法,因为分泌到生物体液中的 EV 源自受影响的组织。为了研究与膀胱癌发病机制相关的重要分子,我们从患者尿液中分离 EV,并通过基于质谱的蛋白质组学进行分析。与全尿蛋白质组的比较表明,EV 中的蛋白质鉴定数量增加。对来自对照组和膀胱癌患者的尿 EV 的比较 MS 分析总共鉴定出 1222 种蛋白质。统计分析显示,膀胱癌尿液中共有 56 种蛋白质显著增加,包括表达水平随癌症分期变化的蛋白质(P 值<0.05)。虽然尿液是泌尿科癌症生物标志物发现的有价值的非侵入性标本,但尿液样本存在高度的个体内和个体间变异性。尿 EV 的富集证明了它在提供泌尿系统疾病中生物学相关蛋白质的有针对性鉴定方面的能力和适用性。